• Email Alerts
  • Careers
  • Contact Us

SCYNEXIS, Inc.

  • Home
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnerships
    • Careers
    • Contact
  • Product
    • ibrexafungerp
    • Patent
  • Pipeline
    • Ibrexafungerp Development Pipeline
    • Clinical Trials
    • Vulvovaginal Candidiasis
    • Refractory Invasive Fungal Infections
    • Invasive Candidiasis
    • Invasive Aspergillosis
  • Science
    • SCYNEXIS Research Platform
    • Publications and Presentations
    • Expanded Access
  • News
    • Press Releases
    • Events
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Stock Data

SCYNEXIS, Inc.

You are now leaving the SCYNEXIS Corporate Website.

I understand Cancel

Press Releases

Investors

Investors

  • Overview
  • News Releases
    • Press Releases
    • Email Alerts
  • Events & Presentations
    • IR Calendar
    • Presentations
  • Governance
    • Leadership
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Financials & Filings
    • SEC Filings
    • Annual Reports
    • Proxy Statements
    • Quarterly Results
    • Key Ratios
  • Stock Data
    • Quote
    • Historical Data
    • Investor Calculator
    • Analyst Coverage
    • Ownership Profile
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News Releases

  • Press Releases
  • Email Alerts

SCYNEXIS Announces Hansoh Pharma’s Application to National Medical Products Administration (NMPA) in China for Phase 3 Trial of Ibrexafungerp for Treatment of Vulvovaginal Candidiasis (VVC)

Sep 13, 2021

SCYNEXIS to Participate in Upcoming Investor Conferences

Sep 8, 2021

SCYNEXIS Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Aug 16, 2021

SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 2, 2021

SCYNEXIS Announces Two Oral Presentations on Pooled Data from the BREXAFEMME (Ibrexafungerp tablets) Phase 3 VANISH Program Demonstrating Consistent Efficacy in the Treatment for Vaginal Yeast Infections at the IDSOG 2021 Virtual Annual Meeting

Jul 29, 2021

SCYNEXIS Announces Three Oral Presentations of Ibrexafungerp Demonstrating Clinical and In Vitro Activity Against Candida Species at the 31st ECCMID

Jul 12, 2021

SCYNEXIS to Present at Ladenburg Thalmann’s Virtual 2021 Healthcare Conference

Jul 7, 2021

SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 2, 2021

SCYNEXIS to Present Commercial Launch Update for BREXAFEMME® (ibrexafungerp tablets)

Jun 23, 2021

SCYNEXIS to Present at the BIO Digital International Convention 2021

Jun 11, 2021
RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...16

    1 Evertrust Plaza, Jersey City, NJ 07302
    (201) 884-5485
    View Google Map

    © 2022 SCYNEXIS, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Contact Us